[ET Net News Agency, 14 September 2021] Morgan Stanley raised its target price for
Shanghai Pharma (02607) to HK$22 from HK$20.5 and maintained its "overweight" rating.
The research house said it raises sales estimates, mainly from the manufacturing segment
assuming an expanded portfolio of products under the Yunnan Baiyao partnership. (RC)